Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on July 8, 2021. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol "CLRB". The report serves as a Regulation FD disclosure regarding an upcoming corporate event.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled presentation by company leadership.
Guidance, Outlook, and Management Commentary
On July 8, 2021, the company announced that James Caruso, President and CEO, will present a company overview and be available for one-on-one meetings at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. The conference is scheduled to be held virtually on July 14, 2021. A press release detailing this event is included as Exhibit 99.1.
Key Facts for Investor Verification
- CEO James Caruso is scheduled to present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021.
- The filing contains no financial data; investors should refer to the company's most recent 10-K or 10-Q for financial metrics.
- The press release referenced in Exhibit 99.1 provides the official details of the conference participation.